Sat, Aug 23, 2014, 11:15 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

jetmanbash 127 posts  |  Last Activity: Aug 19, 2014 11:20 AM Member since: Dec 29, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • jetmanbash jetmanbash Aug 14, 2014 9:50 PM Flag

    ISIS beats VICL on the one day, five day, one month, three months, one year, five year, and max charts on Yahoo. The only period of time where vicl beats ISIS is the six month chart. The short and long term charting definitely shows that ISIS has outperformed vicl. The safety of ANS drugs is really being shown in regards to the use for SMN in new borns, and children. The technical strength has been excellent over the last week, and the fundamentals will continue to shine. vicl is going to get blown out of the water. I look forward to all of you bozos calling ISIS a POS and how it is going down from 120 to whatever you predict. Also, I did have my friend from Jamaica call his aunt OOH BOO Pearl and have her put a jinx on vicl.....OBP is pretty powerful. When vicl goes BK hope though that they at least can have someone pick up that drug to treat melanoma of the mouth so my dog can stay safe on the beach. t

  • Macro, can you give me a report? I know that VICL has done better than ISIS on the six month chart, but on the one day, five day, three month, one year, five year, and max they haven't. Will today help them fill that short-fall. TIA, t

  • Reply to

    Take out offer of $37.50. ceo better take it !

    by tudywaspaid Aug 13, 2014 3:55 PM
    jetmanbash jetmanbash Aug 13, 2014 4:06 PM Flag

    ISIS did it, they broke $35 before vicl broke a buck thirty five. Hey Macro, what was the closing price on vicl? t

  • Reply to

    Take out offer of $37.50. ceo better take it !

    by tudywaspaid Aug 13, 2014 3:55 PM
    jetmanbash jetmanbash Aug 13, 2014 4:05 PM Flag

    Getting more desperate with lies now that ISIS is continuing to go up. t

  • Reply to

    did Rexahn ever provide news on this

    by bcpiii Aug 9, 2014 1:51 PM
    jetmanbash jetmanbash Aug 12, 2014 2:14 PM Flag

    Going to try and get a hold of IR at RNN tomorrow. Will post if I can get the info. Thank you, t

  • Reply to

    10Q could be out at anytime,,,,

    by bcpiii Aug 11, 2014 5:08 PM
    jetmanbash jetmanbash Aug 11, 2014 7:20 PM Flag

    bcpiii, I tried calling IR today. Left a message, will try again tomorrow. Let you know why I find out if I can make contact with them. t

  • jetmanbash by jetmanbash Aug 11, 2014 4:35 PM Flag

    I was highly criticized before when I noted that they would need more funding....and guess they will. You aren't going to be getting a pediatric indication without spending at least three times as much as they did in regards to the adult indication. Also, Mr. Beer is going to want to do more studies to see if he can dig up more people under the heading of HoF. You also have still continued loses, legal expenses, and possibly large penalties. All hidden under the guise of the money might be used for further expanding investments. They also say that they are going to be buying back stock......Is that wise for a growing biotech to do? IMO it isn't, valuable dollars should be spent trying to grow the company. A lot of trickery, hope the CEO paid out of pocket when he had the huge celebration at the Waldorf-Astoria when the announcement was made for approval. It has been all down hill since. t

  • jetmanbash jetmanbash Aug 10, 2014 7:45 PM Flag

    bcpiii, I'm going to actually try and call IR tomorrow. If I get through will let you know what I find out. With ARWR getting much more competitive, as well as ALNY, ISIS, and TKMR, this along with Santaris stealing patents from ISIS, and ALNY stealing patent s from TKMR, I'd expect more of the same in regards to holding their cards to close to their chest. t

  • Reply to

    did Rexahn ever provide news on this

    by bcpiii Aug 9, 2014 1:51 PM
    jetmanbash jetmanbash Aug 9, 2014 11:58 PM Flag

    Thank you bcpiii. You are really adding to this MB instead of those guys that say it is going to be a bad day or a good because.....of what? I do think that Roche did the RNN investors a favor last week when they bought out Santaris. A privately held Dutch ANS company for $450 million. Santaris has a copy-cat pipeline that is way behind the originators of the biomarkers they seek to block, and they deal in LNA's, an ANS that is known to be potent but also toxic. A PhD researcher Bion, who I respect very much still feels that Santaris LNA's are toxic. However, if Roche is willing to take a chance on a company that I just described......assuming my assessment is accurate then IMO RNN with their original, more varied pipeline, with safer drugs should certainly eventually be worth more than that. In other words, IMO the target price should be raised from $3 to around $4.5 based on the going rate in biopharma based on the advancements by other ANS companies and interest by drug starved big pharms at this time. This is IMO price reality at this moment.. Take care, t

  • jetmanbash jetmanbash Aug 9, 2014 5:40 PM Flag

    We have to remember that in the ANS/RNAi game there is a tremendous worry in regards to corporate espionage. At one of the companies that we go to every year for their annual meeting researchers I've know for over 15 years would divulge hardly any info to us. ALNY has certain rights to their GalNac technology. No one knows for certain how or if they can go after anyone in a broad sense, but people are cautious. This delivery system for RNN was developed by Dr. Lee from OSU. It is interesting that in his early work he thought that RNAi was superior to ANS, but he has devleoped the delivery system for an ANS drug.....the one for RNN. ANS drugs are being found to be much more versitle than RNAi drugs that for now can only really get to the liver. If RNN has a good ANS backbone, and many more potential drugs in the pipeline this could be a major player in that space. The RNA field is burgeoning and looks to be able to match or surpase Mab's some day. They will be cheaper to make, not as complicated, they for the most part won't have to be refrigerated, and they will be able to block targets that Mab's probably won't in a lot of cases. t

  • Reply to

    did Rexahn ever provide news on this

    by bcpiii Aug 9, 2014 1:51 PM
    jetmanbash jetmanbash Aug 9, 2014 5:33 PM Flag

    These ligand delivery systems can get up to 60 fold more drug to the target than without their use. In regards to ANS and RNAi these carriers are all the rage, and for good reason. You couple maybe the number one biomarker for CA....AKT1 along with this elegant potent system and you may not hit on all targets with success, but your chances for several are quite good IMO. t

  • jetmanbash jetmanbash Aug 9, 2014 5:29 PM Flag

    ISIS will break $35 again before vicl breaks $1.35 again. We'll have to see. Glad I sold my vicl, but I would be willing to try their one product for my dog if he gets the dreaded melanoma of the mouth. I wonder how many cases of that a vet would see in 35 years of practice.....kind of like how many cases of GIST tumors a physician might see in 35 years of practice. t

  • Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population
    Journal of Oral Pathology & Medicine, 08/05/2014 Clinical Article

    Wang Y, et al. – The aim of this study was to investigate the possible association between AKT1 gene polymorphisms and oral squamous cell carcinoma (OSCC) in Chinese Han Population. The results indicated that rs1130214 and rs3803300 were related to OSCC susceptibility in Chinese Han Population. In addition, rs3730358 might be associated with progression–free survival time of OSCC patients, suggesting that this SNP could be a potential prognosis marker for OSCC.

  • VNN has learned that vicl is in talks in regards to a merger. They may change their name to vicl Dollar to fit in with the suitors Dollar General and Family Dollar. You would be able to get your dog vaccinated for a dollar at one of their stores. t

  • Reply to

    Ebola and ISIS- 200 million gift -US goverment -

    by amgnjim Aug 3, 2014 10:43 PM
    jetmanbash jetmanbash Aug 3, 2014 10:59 PM Flag

    What are you trying to convey if you could please elaborate? ISIS has no program for Ebola virus or any of the hemorrhagic fever viruses for that matter. t

  • When you look under the hood at vicl's pipleline there is a lot to be amazed about in regards to how puny it is. The have two drugs going almost for the same thing, that being CMV. They have my favorite so that I can have my dog roam on the beach without too much worry.....that being for canine melanoma of the mouth. They also have a drug for dengue fever which I don't believe is the best drug out there for this. And their flagship drug for HSV2 which again I don't believe is the best drug out there. They also have this vaccine for pregnant women for HSV2 which strikes me as really funny as they are going to have one heck of a time doing the research in regards to the drug as it will be for an indication for pregnant women.......ever see how hard it is to get a drug approved for pregnant women???? I didn't see any partnerships except for with Astellas. I see a two cylinder engine under the hood. This is David Favorite reporting for the VNN. t

  • Reply to

    $AEGR Up Sharply in After Hours Trading...

    by aniustudent Jul 29, 2014 4:21 PM
    jetmanbash jetmanbash Aug 2, 2014 11:15 PM Flag

    A couple of corrections: The fact that he CFO and CMO reports that there are 1 in 500 patients with HeF does not mean necessarily that there are more than one in 850K at most, and probably one in a million with HoF. He quotes an already known old number of one in 500 for HeF and trys to impress upon people that relatively low number that has been known for a long time and convince you that thus there are probably more than one in a million people with HoF......another number has been known for a long time. Management did dodge a major incident with this last CC, but problems remain and it will be challenging to make end of year numbers. Time, like in options will be AEGR's worst enemy. t

  • jetmanbash jetmanbash Aug 2, 2014 5:54 PM Flag

    You're going to find out that the longer you hold out on a partnership if the data looks good the better off you will do. Big pharma is really hurting for new drugs and new ideas. Most of big pharma is now willing to sell-off their legacy drugs to go after the newer, more profitable areas like CA and orphan drugs. These three meds from RNN have huge potential. Also, RNN's ability to maybe deliver older, more toxic by effective generics right to the target may help those old drugs become franchises again. Huge upside and very little risk with this stock IMO. One just has to know what they can potentially lose, and be able to sleep at night. Their combination of an ANS drug with a delivery system is ahead of the times. All of the RNAi companies with maybe the exception of IDRA are going that way, and some of the ANS companies are going that way as well with their GalNac delivery systems. These guys at RNN will give you as good a chance of making it big as any company this small can. t

  • Reply to

    $AEGR Up Sharply in After Hours Trading...

    by aniustudent Jul 29, 2014 4:21 PM
    jetmanbash jetmanbash Aug 2, 2014 3:53 PM Flag

    That last CC wasn't terrible, but it wasn't all that good. They didn't reduce guidance AGAIN as they already had done that. I don't know if anyone can dogmatically say that the decision in Germany had anything to do with the drug itself. It may have everything to do with the drug itself, esp. price. The EU, NICE etc. are very price point sensitive. With all of the time that the company had to prepare for that report.....how come it wasn't done right if it had to do with the way the report was written. That in and of itself shows some incompetence. The only themes from that CC was that they made their lowerr goal, they think that they hired enough people and that it is coming through, that they think that they will really expand in Brazil......kind of doubtful, and they keep looking for more brighter pastures. The quote about 1 in 500 for HeF true, but that doesn't make it like there will be more than say 1 in 850K to 1 in one million people worldwide. Also, the market needs to figure in the cost of pursuing a pediatric indication for juxta.....it won't be anywhere near as easy as it was with the 23 patient single armed study for adults. t

  • jetmanbash jetmanbash Aug 2, 2014 3:46 PM Flag

    At least compared to the CEO of vicl Dr. Crooke wasn't named one of the worst CEO's in 2013, probably he was the worst by waiting and waiting before having the data released on their last failure drug. Also, vaccines can be more dangerous than any medication. Remember the swine flu immunization with President Gerald Ford, how about the Lyme's disease vaccination, or the recent one that GSK had trouble with in regards to the flu. Vaccines also can contribute to Gillian-Barre. And as an investment, they aren't that hot either. The main question for vicl is can they prove that they are keepin up with the technology in immunology and that is doubtful. Most of big pharma is putting their resources into immunology to fight CA. MRK, BMY, NVS and others, you also have the CART vaccine companies of which NVS is one. vicl has challenges as demonstrated by its share price, its lack of particiaption in the biotech run, and the market in general. One more flop and they will flip into BK. I'd pick a new different champion against ISIS..... t

AEGR
30.14+0.03(+0.10%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.